Securing Minority Genomic Data and Reducing Healthcare Disparities

The U.S. National Cancer Institute (NCI) has completed an observational study (NCT01251900) to investigate the prevalence of BRCA1 and BRCA2 gene mutations among Latinx women. Existing precision medicine data has largely been skewed toward Caucasian populations, creating significant limitations in diagnosing and developing treatment strategies for minority patients. This study analyzed saliva samples and clinical data from 266 Latinx breast cancer patients to ensure genetic diversity and contribute to reducing healthcare disparities across ethnic groups. Notably, Latinx women have a high genetic risk but their genetic testing rates are 4 to 5 times lower than those of Caucasians, making this data a crucial foundation for addressing unmet clinical needs.

Association with Triple-Negative Breast Cancer and Refinement of Targeted Therapy Strategies

According to the study results, Latinx patients with BRCA gene mutations showed a significantly higher incidence of triple-negative breast cancer (TNBC). TNBC is a difficult-to-treat disease because it lacks hormone receptors and HER2 protein, making targeted therapy challenging and recurrence risk high. The correlation between genomic data and tumor pathology in Latinx patients revealed through this clinical trial is expected to accelerate the development of next-generation companion diagnostics. This will serve as a key indicator for refining the stratification of patients for PARP inhibitors such as AstraZeneca's Lynparza (generic name: olaparib) and Pfizer's Talzenna (generic name: talazoparib).

Market Expansion through Low-Cost Sequencing Technology

One of the key achievements of this study is the use of next-generation sequencing (NGS) technology to sequence the BRCA1/2 coding regions at a low cost of approximately USD 85 per participant. The high cost of genetic testing has long been a major barrier to access for minority patients. By significantly reducing the diagnostic unit cost, the speed of clinical screening is expected to increase, and the number of potential treatable patients is projected to grow substantially. This will allow global pharmaceutical companies to efficiently screen patients with diverse ethnic backgrounds and recruit clinical trial participants more rapidly, ultimately shortening development timelines.

Accelerated Market Penetration by Global Pharmaceutical Companies

The global PARP inhibitor market is expected to grow rapidly, reaching approximately USD 4.8 to 6.8 billion by 2025, with Lynparza projected to generate USD 3.07 billion in revenue in 2025. As specific data on BRCA mutation prevalence in underrepresented populations such as Latinx patients becomes clearer, the potential market size is expected to expand further. Biopharma companies now have strong clinical evidence to diversify their targeted oncology portfolios in response to ethnic genetic variations. In the long term, the accumulation of genomic data will serve as a decisive competitive advantage in obtaining companion diagnostic and clinical trial design approvals from global regulatory agencies such as the U.S. Food and Drug Administration (FDA).